Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease.
Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease.
复制标题
间充质干细胞及其在炎症性肠病中的治疗应用
DOI：
10.18632/oncotarget.16682
复制
发表时间：
2017-06-06
期刊：
影响因子：
--
通讯作者：
Xu W
中科院分区：
文献类型：
--
作者：
Mao F;Tu Q;Wang L;Chu F;Li X;Li HS;Xu W
间充质干细胞或基质细胞 (MSC) 是非造血干细胞，可通过自我更新和分化、支持血管生成和组织细胞存活以及限制炎症等机制促进组织再生。 MSC 最初是在来自骨髓和其他器官的细胞的长期培养物中被鉴定和扩增的；它们的天然特性最近被限制在血管化组织中的周细胞和外膜细胞中。间充质干细胞的多能性以及营养和免疫抑制作用促进了其在涉及组织炎症和免疫紊乱（包括炎症性肠病）的许多疾病的临床应用中的快速发展。尽管已经建立了定义 MSC 的标准，但由于其天然异质性，它们的治疗功效在不同研究中存在显着差异。因此，了解 MSC 的生物学和免疫学特征对于标准化和优化基于 MSC 的治疗至关重要。在这篇综述中，我们重点介绍了间充质干细胞介导的组织修复和免疫抑制所涉及的细胞和分子机制。我们还提供了基于 MSC 的临床试验的最新进展，并详细讨论了基于 MSC 的细胞疗法治疗炎症性肠病的情况。
Mesenchymal stem or stromal cells (MSCs) are non-hematopoietic stem cells that facilitate tissue regeneration through mechanisms involving self-renewal and differentiation, supporting angiogenesis and tissue cell survival, and limiting inflammation. MSCs were originally identified and expanded in long-term cultures of cells from bone marrow and other organs; and their native identity was recently confined into pericytes and adventitial cells in vascularized tissue. The multipotency, as well as the trophic and immunosuppressive effects, of MSCs have prompted the rapid development of clinical applications for many diseases involving tissue inflammation and immune disorders, including inflammatory bowel disease. Although standard criteria have been established to define MSCs, their therapeutic efficacy has varied significantly among studies due to their natural heterogenicity. Thus, understanding the biological and immunological features of MSCs is critical to standardize and optimize MSCs-based therapy. In this review, we highlight the cellular and molecular mechanisms involved in MSCs-mediated tissue repair and immunosuppression. We also provide an update on the current development of MSCs-based clinical trials, with a detailed discussion of MSC-based cell therapy in inflammatory bowel disease.